Clinical trial NCT06998888: Determining the Effectiveness of Remote Monitoring of Cancer Patients With Oral Cancer Treatment Using Caaring® Software
Official title: Determining the Effectiveness of Remote Monitoring of Cancer Patients Undergoing Outpatient Oral Cancer Treatment Using Caaring® Software
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cancer
Keywords: Caaring
Digital Care
Cancer
Remote patient monitoring
Online telemonitoring
DTx
Lead sponsor: Persei Vivarium
Sponsor class: OTHER
Collaborators: name: Effice Servicios Para la Investigacion S.L.
First posted: 2025-05-31
Enrollment: 194
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The goal of this clinical trial investigation with device is to determinate the efficacy of the remote monitoring in cancer patients with a software called Caaring® a través del cumplimento terapéutico y de dosis.

The main question it aims to answer is if the development of a self-management platform (Caaring®) empowers cancer patients throughout their illness, reducing the number of in-person and telephone visits assisted by specialized medical and nursing staff. For this, researchers will compare the assessments between the two groups.

This is a randomized study with two arms. Online telemonitoring group: The follow-up of these patients will be carried out prospectively remotely through the Caaring® platform. And Prospective Control group: The data of these patients are collected prospectively for their routine medical visits for 12 weeks after their inclusion.

Caaring group patients must have sufficient technological skills to use a smartphone.

Detailed description: This is a longitudinal, comparative non-inferiority, multicenter, with 2 arms Medical Device Clinical Trial.

The protocol and informed consent documents have been reviewed and approved by the hospital human subjects reviewboard and the study will be performed in accordance with the Declaration of Helsinki

Eligibility criteria: Inclusion Criteria:

* Patients who provide informed consent.
* Age ≥18 years.
* Oncology patients undergoing active outpatient oral therapy with: capecitabine, cyclin inhibitors, hormonal therapies, TKI inhibitors, monotherapy with or without intravenous therapy.
* Oncology patients undergoing active outpatient oral oncology treatment expected within 12 weeks of inclusion.
* Patients who must demonstrate sufficient technological skills to operate a smartphone through the "technological skills questionnaire."
* Patients who do not meet the exclusion criteria.

Exclusion Criteria:

* Patients with cognitive or sensory difficulties or insufficient command of Spanish language that, in the opinion of the healthcare professional conducting the recruitment, makes it difficult to understand the questions posed in the surveys, scales, or instruments used in the study, provided they do not have a legal representative capable of participating in the study.
* Patients for whom it is anticipated that follow-up will not be possible due to a change of residence.
* Patients who are participating in any other clinical trial or experimental study at the time of recruitment. Participation in observational studies will not be an exclusion criteria.
* Patients whose primary diagnosis is a mental illness or another poorly controlled medical condition.
* Terminally ill patients and/or those receiving palliative care according to the criteria of SECPAL (Spanish Society of Palliative Care).
* Institutionalized patients.
* Patients who, according to the recruiting professional's assessment, are not considered eligible for inclusion because they are undergoing specific follow-up care in other units (hemodialysis, transplants, etc.) requiring mandatory hospital visits less frequently than once every two months.
* Patients who do not demonstrate sufficient technological skills to use a smartphone through the "technological skills questionnaire."

Primary outcomes:
measure: Percentage of adherence to treatment prescribed for cancer
timeFrame: 12 weeks
Secondary outcomes:
measure: Percentage of patients with al least 80% of data completed
timeFrame: Week 12
measure: Percentage of patients with 100% of data completed
timeFrame: Week 12
measure: Changes in the use of health resources
timeFrame: Day 0 and Monthly up to 12 weeks
measure: Patient satisfaction with the software Caaring
timeFrame: Week 12
Other outcomes:
Locations:
city: Boadilla del Monte
country: Spain
facility: Hospital Universitario HM Monteprincipe
state: Madrid
city: Hortaleza
country: Spain
facility: Hospital Universitario HM Sanchinarro
state: Madrid
city: Mostoles
country: Spain
facility: Hospital Universitario HM Puerta del Sur
state: Madrid
Study officials:
References: